pSivida’s lead investigational new product is a three-year sustained-release implant containing fluocinolone acetonide , a corticosteroid, in late stage clinical development for the treatment of posterior uveitis. The product utilizes the proven Durasert Technology platform.
- pSivida to Present at the 2018 BIO CEO & Investor Conference
- pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
- pSivida’s Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months